Key Segmentation
By Drug Type
-
Axicabtagene Ciloleucel (Yescarta)
-
Brexucabtagene Autoleucel (Tecartus)
-
Ciltacabtagene Autoleucel (Carvykti)
-
Idecabtagene Vicleucel (Abecma)
-
Lisocabtagene Maraleucel (Breyanzi)
-
Tisagenlecleucel (Kymriah)
-
Others
By Indication
-
Acute Lymphoblastic Leukemia
-
Non-Hodgkin Lymphoma
-
Multiple Myeloma
By End-user
-
Hospitals
-
Oncology Treatment Centers
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
-
US
-
Canada
-
Mexico
Europe
-
Eastern Europe
-
Poland
-
Romania
-
Hungary
-
Turkey
-
Rest of Eastern Europe
-
-
Western Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Netherlands
-
Switzerland
-
Austria
-
Rest of Western Europe
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Vietnam
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
Middle East
-
UAE
-
Egypt
-
Saudi Arabia
-
Qatar
-
Rest of the Middle East
Africa
-
Nigeria
-
South Africa
-
Rest of Africa
Latin America
-
Brazil
-
Argentina
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Product Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Product Matrix which gives a detailed comparison of the product portfolio of each company
-
Geographic Analysis
-
Additional countries in any of the regions
-
Company Information
-
Detailed analysis and profiling of additional market players (Up to five)
Frequently Asked Questions
Ans: North America is the dominant region in the CAR T-Cell Therapies market.
Ans: The high cost of treatment limits the adoption of Car-t cell therapy.
Ans: The rising prevalence of hematological cancers, such as non-Hodgkin’s lymphoma (NHL) and leukemia, is a critical driver for the growth of the CAR-T cell therapy market.
Ans: The estimated compound annual growth rate is 26.0% during the forecast period for the CAR T-Cell Therapies market.
Ans: The projected market value of the CAR T-Cell Therapies market is estimated at USD 5.42 Billion in 2024 and is expected to reach USD 34.42 billion by 2032.